Search Results 201-210 of 10599 for Terminal
Terminal illness; Active Sepsis/Bacteremia. Participating Mayo Clinic locations. Study statuses change often. Please contact the study team for the most up-to ...
Participation eligibility · Have advanced terminal cancer, severe depression, or other psychiatric disorder or a sleep disorder other than insomnia (sleep apnea, ...
* Has screening N-terminal prohormone B-type natriuretic peptide (NT-proBNP) \>300 ng/L and \<8500 ng/L; In patients with permanent or persistent atrial ...
Terminal illness other than HF, such as malignancy, or with a life expectancy of less than 1 year as determined by the enrolling clinician-investigator.
If a patient has between 1 and 2 years of interaction, then a “terminal event” will be appended to the data. If a patient has more than 2 years of ...
... terminal half-life of luspatercept based on multiple-dose pharmacokinetics [PK] data) after discontinuation of study therapy. Male subjects must: Practice ...
a plasma B-type Natriuretic Peptide (BNP) level ≥ 300 pg/ml or N-terminal prohormone of brain natriuretic peptide (NT-proBNP) ≥1800pg/ml measured during a ...
* Known allergies to any of the components of the compression. * Terminal illness or current cancer therapy with chemotherapy * Inability to undergo ongoing ...
... terminals, to assess the pharmacokinetic (PK) profile of BIIB054 and to evaluate the immunogenicity of BIIB054. Participation eligibility. Participant ...
This brain disease is likely caused by repeated concussions, but this condition isn't well understood.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Hurry to 3X your gift’s impact on cancer research and care!